gatifloxacin has been researched along with Osteomyelitis in 10 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Osteomyelitis: INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of oral gatifloxacin was compared to that of standard parenteral antibiotic therapy (nafcillin) for the treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in a rabbit model." | 7.71 | Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. ( Calhoun, JH; Mader, JT; Shirtliff, ME, 2002) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 5.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| "The effectiveness of oral gatifloxacin was compared to that of standard parenteral antibiotic therapy (nafcillin) for the treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in a rabbit model." | 3.71 | Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. ( Calhoun, JH; Mader, JT; Shirtliff, ME, 2002) |
| "Osteomyelitis is a difficult to treat bacterial infection of the bone." | 1.35 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. ( Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F, 2008) |
| "Osteomyelitis is an infection located in bone and a notoriously difficult disease to manage, requiring frequent and heavy doses of systemically administered antibiotics." | 1.35 | Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. ( Arhin, FF; Delorme, D; Dietrich, E; Fadhil, I; Far, AR; Ferreira, SS; Houghton, TJ; Kang, T; Lafontaine, Y; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Sarmiento, I; Tanaka, KS; Viens, F, 2008) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 1.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, KS | 2 |
| Houghton, TJ | 2 |
| Kang, T | 2 |
| Dietrich, E | 2 |
| Delorme, D | 2 |
| Ferreira, SS | 2 |
| Caron, L | 1 |
| Viens, F | 2 |
| Arhin, FF | 2 |
| Sarmiento, I | 2 |
| Lehoux, D | 2 |
| Fadhil, I | 2 |
| Laquerre, K | 2 |
| Liu, J | 2 |
| Ostiguy, V | 2 |
| Poirier, H | 2 |
| Moeck, G | 2 |
| Parr, TR | 2 |
| Rafai Far, A | 1 |
| Lafontaine, Y | 1 |
| Far, AR | 1 |
| Makiishi, J | 2 |
| Matsuno, T | 4 |
| Ito, A | 4 |
| Sogo, Y | 4 |
| Satoh, T | 4 |
| Kimishima, K | 2 |
| Tamazawa, G | 3 |
| Soundrapandian, C | 2 |
| Datta, S | 2 |
| Kundu, B | 1 |
| Basu, D | 2 |
| Sa, B | 2 |
| Miyai, T | 2 |
| Kitahara, K | 1 |
| El-Kamel, AH | 1 |
| Baddour, MM | 1 |
| Nakamura, C | 1 |
| Yamazaki, A | 1 |
| Shirtliff, ME | 1 |
| Calhoun, JH | 1 |
| Mader, JT | 1 |
10 other studies available for gatifloxacin and Osteomyelitis
| Article | Year |
|---|---|
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Orga | 2008 |
Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Amines; Animals; Cell Line; Diphosphonates; Female; Fluoroquinolones; Molecular Structure; Osteomyel | 2008 |
In vitro/in vivo evaluation of the efficacy of gatifloxacine-loaded PLGA and hydroxyapatite composite for treating osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Biocompatible Materials; Bone Regeneration; De | 2017 |
Effects of gatifloxaine content in gatifloxacine-loaded PLGA and β-tricalcium phosphate composites on efficacy in treating osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Biocompatible Materials; Calcium Phosphates; C | 2016 |
Porous bioactive glass scaffolds for local drug delivery in osteomyelitis: development and in vitro characterization.
Topics: Anti-Infective Agents; Biocompatible Materials; Drug Delivery Systems; Fluconazole; Fluoroquinolones | 2010 |
Local drug delivery system for the treatment of osteomyelitis: In vitro evaluation.
Topics: Anti-Infective Agents, Local; Biocompatible Materials; Delayed-Action Preparations; Drug Administrat | 2011 |
Gatifloxacine-loaded PLGA and β-tricalcium phosphate composite for treating osteomyelitis.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Bacteriological Techniques; Bacteroides fragili | 2011 |
Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Disease Models, Animal; Drug Carriers; Female; | 2007 |
Antibiotic-loaded poly-epsilon-caprolactone and porous beta-tricalcium phosphate composite for treating osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Calcium Phosphates; Fluoroquinolones; Gatifloxacin; Male; Osteomyeli | 2008 |
Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Disease Models, Animal; Fluoroquinolones; Gati | 2002 |